CA3128401A1 — Psma binding dual mode radiotracer and -therapeutics
Assigned to Technische Universitaet Muenchen · Expires 2020-08-06 · 6y expired
What this patent protects
The present invention relates to a compound according to formula (V): or a pharmaceutically acceptable salt thereof, optionally containing a chelated radioactive cation and wherein F is optionally 18F.
USPTO Abstract
The present invention relates to a compound according to formula (V): or a pharmaceutically acceptable salt thereof, optionally containing a chelated radioactive cation and wherein F is optionally 18F.
Drugs covered by this patent
- Posluma (FLOTUFOLASTAT F-18 GALLIUM) · Blue Earth
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.